Tethys Raises $33M in VC Financing, Loan | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Tethys Bioscience today said that it has raised $33 million in venture financing and a loan.

The Emeryville, Calif.-based firm, which is developing biomarker-based, disease-risk tests, has raised $23 million in venture financing through new investors, including Greenspring Associates and Paul Capital Investments, and its current investors. The funds are part of Tethys' Series D round, bringing the total funding in that round to $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.